Clinical Trials
-
Principal Investigator:
Nobuko Hijiya, MDThis study will utilize an investigational drug combination (also known as the study drugs) called relatlimab and nivolumab as a possible treatment for recurrent/relapsed (returned) or refractory (treatment-resistant) cHL and NHL. An investigational drug combination is one that has not been approved by regulatory agencies, such as the United States (US) Food and Drug Administration (FDA), European Union (EU) European Medicines Agency (EMA), or others. The purpose of this study is to learn about the safety and effectiveness of nivolumab and relatlimab in participants with recurrent/relapsed or... -
Principal Investigator:
Joyce Elaine Yu, MDThe study population includes up to 110 adult male and female participants ages 18-55 years. Participants may have multiple food allergies but must be peanut allergic in order to be included. Safety assessments will include the following: physical examination, vital signs, laboratory evaluations, and ECG (electrocardiogram). -
Principal Investigator:
Dana Goldner, MDThe main purpose of this study is to determine how safe and effective fazirsiran is in patients with alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD) compared to placebo. Eligible participants will receive either fazirsiran or placebo for about 4 years. This is a double-blind study, so the study doctors and participants will not know whether or not they are receiving fazirsiran or placebo. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC). -
Principal Investigator:
Steven J. Lobritto, MDTReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three-arm clinical trial of immunosuppressive therapy for children with acute liver failure. This is a double-blind study, so the study doctors and participants will not know to which arm the participants are assigned. The study will determine if corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition, as compared to supportive care. Participants will be enrolled while they are hospitalized for acute liver failure, and will continue to be... -
Principal Investigator:
Steven J. Lobritto, MDTReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three-arm clinical trial of immunosuppressive therapy for children with acute liver failure. This is a double-blind study, so the study doctors and participants will not know to which arm the participants are assigned. The study will determine if corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition, as compared to supportive care. Participants will be enrolled while they are hospitalized for acute liver failure, and will continue to be... -
Principal Investigator:
Melissa S. Stockwell, MD, MPHWe are seeking volunteers who have been recently diagnosed with influenza virus infection by either rapid diagnostic assay or RT-PCR in the last 5 days, and live in a household with at least one other person. The study, also known as RVTN Flu will be looking at household transmission of influenza. Once someone and their household contacts are enrolled, they will be followed for 7 consecutive days to identify new virus infections among household members. Follow-up will include interviews/questionnaires, daily data collection from all participating household members for 7 days, daily self-... -
Principal Investigator:
Mercedes Martinez, MDThe purpose of this clinical research study is to learn more about the use of the investigational study drug, volixibat, for the treatment of pruritus (itching) associated with primary sclerosing cholangitis or PSC. Volixibat is a drug that is designed to lower circulating bile acid levels may lead to the itching in patients with PSC. Eligible patients will be randomly assigned to volixibat or to placebo for 28 weeks. This is a double-blind study, so the study doctors and participants will not know to which arm the participants are assigned. After completing 28 weeks of treatment, if eligible...